What question did this study set out to answer?

To evaluate the efficacy of crizanlizumab in preventing vaso-occlusive crises and hospitalizations in sickle cell disease.

December 8, 2025Blood

Efficacy of crizanlizumab in preventing vaso-oclusive crisis and hospitlalizations in sickle cell disease

View Full Paper

Ask AI

Bookmark

Authors

RJReyad Al JabiriLincoln Medical Center FAFAIQ ALDARAB'AHLincoln Medical Center

Discussion

Member takes

Implication

Retrospective analysis finds crizanlizumab increased vaso-occlusive crisis and hospitalization in sickle cell anemia patients, suggesting inferior outcomes.

Key Points

To evaluate the efficacy of crizanlizumab in preventing vaso-occlusive crises and hospitalizations in sickle cell disease.
Retrospective cohort analysis utilizing the TriNetX database.
Included adults with HbSS SCD who experienced at least one VOC prior to treatment.
Used propensity score matching to adjust for confounders such as age, gender, and Hb levels.
Patients on crizanlizumab had higher rates of VOCs across all time points: 3, 6, 12, and 36 months.
Hospitalization risk was elevated for crizanlizumab users at 3 months, 1 year, and 3 years compared to non-users.
Relative risk of VOCs and hospitalizations was significantly higher in the crizanlizumab cohort.

Cite This Study

Jabiri et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e2f8 https://doi.org/10.1182/blood-2025-7962

View Full Paper

Ask AI

Bookmark

Implication

Retrospective analysis finds crizanlizumab increased vaso-occlusive crisis and hospitalization in sickle cell anemia patients, suggesting inferior outcomes.

Efficacy of crizanlizumab in preventing vaso-oclusive crisis and hospitlalizations in sickle cell disease

Discussion

Member takes

Implication

Key Points

Cite This Study

Efficacy of crizanlizumab in preventing vaso-oclusive crisis and hospitlalizations in sickle cell disease

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider